LOSS OF UBIQUITIN LIGASE STUB1 AMPLIFIES IFNγ-R1/JAK1 SIGNALING AND SENSITIZES TUMORS TO IFNγ
Apriamashvili, G.; Vredevoogd, D. W.; Krijgsman, O.; Bleijerveld, O. B.; Ligtenberg, M. A.; de Bruijn, B.; Boshuizen, J.; D'Empaire Altimari, D.; Visser, N. L.; Londino, J. D.; Altelaar, M.; Peeper, D. S.
Show abstract
Despite the success of immune checkpoint blockade (ICB) most patients fail to respond durably, in part owing to reduced interferon gamma (IFNγ) sensitivity. Thus, elevating tumor IFNγ-receptor 1 (IFNγ-R1) expression to enhance IFNγ-mediated cytotoxicity is of potential clinical interest. Here, we show that increased IFNγ-R1 expression sensitizes tumors to IFNγ-mediated killing. To unveil the largely undefined mechanism governing IFNγ-R1 expression, we performed a genome-wide CRISPR/Cas9 screen for suppressors of its cell surface abundance. We uncovered STUB1 as key mediator of proteasomal degradation of the IFNγ-R1/JAK1 complex. STUB1 inactivation amplified IFNγ signaling, thereby sensitizing to cytotoxic T cells, but also inducing PD-L1. STUB1 loss in a rational combination with PD-1 blockade strongly inhibited melanomas in vivo. Clinically corroborating these results, a STUB1-KO gene signature was strongly associated with anti-PD-1 response. These results uncover STUB1 as pivotal regulator of IFNγ tumor signaling and provide a rationale for its inhibition combined with anti-PD-1.Competing Interest StatementD.S.P. is co-founder, shareholder and advisor of Immagene B.V. M.A.L. is co-founder, shareholder and C.E.O. of Immagene B.V. The other authors report no competing financial interests. View Full Text
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 95%
Similar papers in this journal
- A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma 97%
- CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer 95%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 95%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.